News

ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment

ValiRx Plc, a life science company focusing on cancer therapeutics and women's health, has announced that ValiRx subsidiary, ValiSeek Ltd, has entered into an exclusive option agreement to license VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.


Ambrose Healthcare is seeking to develop new treatments for rare diseases and patients managed in hospitals and specialist care. The company, incorporated in 2022, has an internationally experienced leadership team with deep knowledge of the pharmaceutical industry.

Read more

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing

CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing



  • PhysioMimix NASH assay used to provide human-relevant data on compound efficacy for Inipharm’s lead candidate, INI-822

  • Submission represents first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver disease


 

Read more

Discovery Park Ventures expands fund to £3m to invest in more innovative science and technology start-ups

Sandwich, Kent, UK, 4th December 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.

Read more

ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT

Arecor Therapeutics plc

(“Arecor” or the “Group”)


ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT


Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy

Read more

ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Seasoned Life Sciences pharmaceutical physician and leader joins the region’s Life Science & Healthcare membership organisation

 

Read more

ARECOR CONTINUES COLLABORATION WITH LILLY

Arecor Therapeutics plc

(“Arecor” or the “Group”)


ARECOR CONTINUES COLLABORATION WITH LILLY

Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™


Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).

Read more

Spatial biology multi-omics profiling tools for advanced biomedical research

Leading life sciences products and services provider - AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.

Read more

Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London

November 2023


Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London

Read more

Harness Therapeutics secures additional £4 million funding

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases



  • Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis

  • Refined focus on neurodegenerative disease targets

  • Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington’s Disease towards the clinic


 

Read more

Biocair joins Pharma.Aero's pioneering project to elevate cell and gene therapy logistics

Biocair, a leading specialist in cell and gene therapy logistics, is proud to announce its alliance with Pharma.Aero, a global cross-industry collaboration platform. Together, they are driving transformation in the cell and gene therapy (CGT) supply chain.


Cell and gene therapies are a revolutionary way to fight disease in that they offer patients complete personalization of medicine. These time-sensitive and life-changing medicines need logistics solutions as innovative as they are.

Read more

Pages